Navigation Links
Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
Date:12/3/2009

NANJING, China, Dec. 3 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") has initiated a comprehensive investigation into quality issues regarding human use rabies vaccine (vero cell) manufactured by Simcere's subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

On November 23, 2009, Simcere urged the board of Jiangsu Yanshen to replace its general manager and head of quality assurance. Jiangsu Yanshen subsequently decided to implement a total suspension of production in order to improve its quality control systems effective on November 30, 2009.

The SFDA issued a public notice on December 3, 2009 announcing the initiation of a comprehensive investigation into quality issues regarding human use rabies vaccine manufactured by two companies including Jiangsu Yanshen. The SFDA has assigned investigation teams to oversee the provincial administrations' inquiry into the matter and has established a file on Jiangsu Yanshen. Four batches of the human use rabies vaccine manufactured by Jiangsu Yanshen between July and October 2008 have been found to have quality problems. The SFDA has ordered Jiangsu Yanshen to halt marketing and production of all products including human use rabies vaccine and has organized experts to provide an assessment of risks presented by the problem vaccine. According to the SFDA announcement, patients who received the vaccine in question may receive medical consultations with their original inoculation hospitals. The resumption of production and sales at Jiangsu Yanshen as well as potential penalties will be subject to the findings of the investigation.

Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group, commented: "As a responsible company which always prioritizes the safety of our patients and customers, Simcere has urged Jiangsu Yanshen to actively cooperate with the SFDA's investigation. We will keep the market updated of any further developments in a timely manner."

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release and the section under "Financial Outlook" contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at http://www.sec.gov . Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication stroke management medication and biopharmaceutical drugs such as vaccines. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, orthopaedics and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .

    For more information, please contact:

    Investor and Media Contacts:
     Email: ir@simcere.com

    In Nanjing:
     Frank Zhao
     Chief Financial Officer
     Simcere Pharmaceutical Group
     Tel: +86-25-8556-6666 x8818

    In the United States:
     Kate Tellier
     Brunswick Group
     Tel: +1-212-333-3810

    In Beijing:
     Ruirui Jiang
     Brunswick Group
     Tel: +86-10-6566-2256

    In Hong Kong:
     Joseph Lo Chi-Lun
     Brunswick Group
     Tel: +852-3512-5000

SOURCE Simcere Pharmaceutical Group


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
2. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
3. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
4. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
5. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
6. KV Pharmaceutical Enters Into Employment Agreement with Interim President and Chief Executive Officer David A. Van Vliet
7. Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends
8. Reportlinker Adds Latin American Pharmaceutical Market Outlook to 2014: Policy environment, market analysis, forecasts and growth opportunities
9. Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies
10. Lilly Releases Latest Value of Medicine Resource Guide About Key Issues Facing the Pharmaceutical Industry
11. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
(Date:1/18/2017)... SAN DIEGO , Jan. 18, 2017 /PRNewswire/ ... manufacturing solutions for cell and advanced therapies , ... the French biopharmaceutical company developing "tumor starvation" treatments ... unmet medical needs. Under the agreement, Invetech will ... products based on Erytech,s proprietary ERYCAPS technology platform, ...
(Date:1/18/2017)... 18, 2017  Tarix Orphan LLC today announced that ... Rare Pediatric Disease (RPD) designation for the company,s drug ... Bullosa (RDEB), a rare genetic skin disorder. There are ... limited to supportive care. "The RPD designation ... previously granted by the FDA in this indication," said ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... At Hallmark Nameplate, ... announce that they have achieved certification to ISO 13485. This certification is another way ... up to date products and services that they need. , The ISO 13485 Certification ...
(Date:1/18/2017)... NH (PRWEB) , ... January 18, 2017 , ... ... launch of the revolutionary Active Brake Technology (ABT), an innovative braking system that ... , Active Brake Technology addresses one of the biggest concerns of beginner and ...
(Date:1/17/2017)... NY (PRWEB) , ... January 17, 2017 , ... Gym ... opening of a new showroom at South Dixie Hwy in Miami, FL. , “We ... at Gym Source. “The new innovative in-store concept is designed to give clients a ...
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for Pink ... Pink Elephant recognizes a new product or service developed by an IT services vendor ... The award highlights original innovations that were released in 2016, either as a major ...
(Date:1/17/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider , ... Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that Mirror ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration as ...
Breaking Medicine News(10 mins):